These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31797421)

  • 1. Incorporating patient-reported outcomes in dose-finding clinical trials.
    Lee SM; Lu X; Cheng B
    Stat Med; 2020 Feb; 39(3):310-325. PubMed ID: 31797421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
    Andrillon A; Biard L; Lee SM
    J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes.
    Alger E; Lee SM; Cheung YK; Yap C
    ESMO Open; 2024 Jul; 9(7):103626. PubMed ID: 38968929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
    Yuan Y; Yin G
    Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hierarchical models for sharing information across populations in phase I dose-escalation studies.
    Cunanan KM; Koopmeiners JS
    Stat Methods Med Res; 2018 Nov; 27(11):3447-3459. PubMed ID: 28480828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2023 Jun; 42(14):2409-2419. PubMed ID: 37012897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay of priors and skeletons in two-stage continual reassessment method.
    Iasonos A; O'Quigley J
    Stat Med; 2012 Dec; 31(30):4321-36. PubMed ID: 22893483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.